Immunotherapy Agents, Combinations to Compete for Frontline NSCLC – OncLive
|
Immunotherapy Agents, Combinations to Compete for Frontline NSCLC
OncLive For example, the PD-1 inhibitor pembrolizumab (Keytruda) is the sole immunotherapy agent approved in the first-line setting for patients with NSCLC; however, many other immunotherapy agents and combination regimens are in development that are aimed … |
